The introduction of intravitreal injections (IVI) of vascular endothelial growth factor inhibitors (anti-VEGF) has revolutionized the prognosis of neovascular age-related macular degeneration (nAMD), and they are currently the gold standard of treatment [1]. Here, VEGFA is linked to wet macular degeneration.